Upstream Bio, Inc. Common Stock (UPB) Stock Price
UPBStock
$6.69−60.08%52W
Market Cap$366.42M
P/E—
PEG Ratio—
Div yield—
Beta2.07
UPB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-27.46%
Price vs S&P 500 (4W)2.66%
VGM Score47.29
UPB Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.76 | -$0.73 | +4.06%(+$0.03) | |
| Q1 2026 | -$0.75 | -$0.75 | +0.50%(+$0.00) | |
| Q4 2025 | -$0.70 | -$0.78 | -11.58%(-$0.08) | |
| Q3 2025 | -$0.77 | -$0.63 | +17.75%(+$0.14) | |
| Q2 2025 | -$0.61 | -$0.74 | -21.24%(-$0.13) |
UPB Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.00
3.92
3.92
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
UPBUpstream Bio, Inc. Common Stock | D | B | D | $6.69 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Upstream Bio, Inc. Common Stock
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a TSLP receptor antagonist for inflammatory diseases. The company is initially targeting severe respiratory disorders where TSLP is a validated pathological driver. This upstream target addresses multiple immune-mediated disease indications.